Indivior PLC Ordinary Shares - Asset Resilience Ratio
Indivior PLC Ordinary Shares (INDV) has an Asset Resilience Ratio of 0.07% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2024)
This chart shows how Indivior PLC Ordinary Shares's Asset Resilience Ratio has changed over time. Check strategic asset allocation of Indivior PLC Ordinary Shares to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Indivior PLC Ordinary Shares's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see INDV company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.00 Million | 0.07% |
| Total Liquid Assets | $1.00 Million | 0.07% |
Asset Resilience Insights
- Limited Liquidity: Indivior PLC Ordinary Shares maintains only 0.07% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Indivior PLC Ordinary Shares Industry Peers by Asset Resilience Ratio
Compare Indivior PLC Ordinary Shares's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329 |
Drug Manufacturers - Specialty & Generic | 5.92% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Zhejiang Tianyu Pharmaceutical Co Ltd
SHE:300702 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Zhejiang Anglikang Pharmaceutical Co Ltd Class A
SHE:002940 |
Drug Manufacturers - Specialty & Generic | 9.11% |
Annual Asset Resilience Ratio for Indivior PLC Ordinary Shares (2022–2024)
The table below shows the annual Asset Resilience Ratio data for Indivior PLC Ordinary Shares.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.08% | $1.00 Million | $1.32 Billion | -4.73pp |
| 2023-12-31 | 4.81% | $94.00 Million | $1.95 Billion | -1.92pp |
| 2022-12-31 | 6.73% | $119.64 Million | $1.78 Billion | -- |
About Indivior PLC Ordinary Shares
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly … Read more